What is PediaLabs?
PediaLabs operates at the intersection of convenience and clinical precision, offering mobile phlebotomy services that bring essential blood draw and laboratory testing directly to the patient's home or office. While the company maintains a specialized focus on pediatric care, ensuring a gentle and stress-free environment for younger patients, its service model is fully equipped to handle all age demographics. Beyond standard phlebotomy, the company has diversified its portfolio to include immunization testing, DNA diagnostics, and professional phlebotomy training programs. By removing the traditional barriers associated with clinical visits, PediaLabs is effectively decentralizing diagnostic healthcare and improving patient compliance through a highly accessible, service-oriented model.
How much funding has PediaLabs raised?
PediaLabs has raised a total of $50K across 1 funding round:
Debt
$50K
Debt (2025): $50K with participation from Northeast Bank
Key Investors in PediaLabs
Northeast Bank
A regional financial institution providing commercial banking and debt financing solutions to support the growth of established healthcare enterprises.
What's next for PediaLabs?
With this latest infusion of capital, PediaLabs is positioned to transition from a regional service provider to a broader market player. The strategic roadmap likely involves scaling its fleet of certified phlebotomists and investing in proprietary logistics software to optimize appointment routing and sample integrity. As the company matures through its Series B/C stage, management will likely prioritize the expansion of its B2B partnerships with pediatric clinics and corporate wellness programs. Furthermore, the integration of advanced digital health tools will be critical in maintaining the high standard of patient experience that defines their brand, ensuring that PediaLabs remains a leader in the rapidly evolving home-based diagnostic landscape.
See full PediaLabs company page
